Cargando…

Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy

BACKGROUND: Prognostic factors of melanoma with distant metastasis and systemic treatment are only poorly established. This study aimed to analyse the impact of S100B, lactate dehydrogenase (LDH) and the type of treatment on survival in advanced patients receiving systemic treatment. PATIENTS AND ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Weide, Benjamin, Richter, Sabina, Büttner, Petra, Leiter, Ulrike, Forschner, Andrea, Bauer, Jürgen, Held, Laura, Eigentler, Thomas Kurt, Meier, Friedegund, Garbe, Claus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842933/
https://www.ncbi.nlm.nih.gov/pubmed/24312329
http://dx.doi.org/10.1371/journal.pone.0081624
_version_ 1782293009599037440
author Weide, Benjamin
Richter, Sabina
Büttner, Petra
Leiter, Ulrike
Forschner, Andrea
Bauer, Jürgen
Held, Laura
Eigentler, Thomas Kurt
Meier, Friedegund
Garbe, Claus
author_facet Weide, Benjamin
Richter, Sabina
Büttner, Petra
Leiter, Ulrike
Forschner, Andrea
Bauer, Jürgen
Held, Laura
Eigentler, Thomas Kurt
Meier, Friedegund
Garbe, Claus
author_sort Weide, Benjamin
collection PubMed
description BACKGROUND: Prognostic factors of melanoma with distant metastasis and systemic treatment are only poorly established. This study aimed to analyse the impact of S100B, lactate dehydrogenase (LDH) and the type of treatment on survival in advanced patients receiving systemic treatment. PATIENTS AND METHODS: We analysed overall survival of 499 patients from the university department of dermatology in Tuebingen, Germany, with unresectable melanoma at the time point of initiation of first-line systemic therapy. Only patients who started treatment between the years 2000 and 2010 were included. Disease-specific survival was calculated by bivariate Kaplan Meier survival probabilities and multivariate Cox hazard regression analysis. RESULTS: In univariate analysis LDH, S100B, the site of distant metastasis (soft tissue vs. lung vs. other visceral), the presence of brain metastases and the type of treatment (monochemotherapy, polychemotherapy, immunotherapy or biochemotherapy) were associated with overall survival (all p<0.001). In multivariate analysis LDH (Hazard ratio [HR] 1.6 [1.3–2.1]; p<0.001), S100B (HR 1.6 [1.2–2.1]; p<0.001) and the presence of brain metastases (HR 1.5 [1.1–1.9]; p = 0.009), but not the type of treatment had significant independent impact. Among those factors normal S100B was the best indicator of long-term survival, which was 12.3% after 5 years for this subgroup. CONCLUSION: Serum S100B is a prognostic marker predicting survival at the time of initiation of first-line treatment in unresectable melanoma patients. Compared to the other independent factors LDH and the presence of brain metastases it is most appropriate to predict long-term survival and requires further prospective investigation in patients treated with new and more potent drugs in metastatic melanoma.
format Online
Article
Text
id pubmed-3842933
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38429332013-12-05 Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy Weide, Benjamin Richter, Sabina Büttner, Petra Leiter, Ulrike Forschner, Andrea Bauer, Jürgen Held, Laura Eigentler, Thomas Kurt Meier, Friedegund Garbe, Claus PLoS One Research Article BACKGROUND: Prognostic factors of melanoma with distant metastasis and systemic treatment are only poorly established. This study aimed to analyse the impact of S100B, lactate dehydrogenase (LDH) and the type of treatment on survival in advanced patients receiving systemic treatment. PATIENTS AND METHODS: We analysed overall survival of 499 patients from the university department of dermatology in Tuebingen, Germany, with unresectable melanoma at the time point of initiation of first-line systemic therapy. Only patients who started treatment between the years 2000 and 2010 were included. Disease-specific survival was calculated by bivariate Kaplan Meier survival probabilities and multivariate Cox hazard regression analysis. RESULTS: In univariate analysis LDH, S100B, the site of distant metastasis (soft tissue vs. lung vs. other visceral), the presence of brain metastases and the type of treatment (monochemotherapy, polychemotherapy, immunotherapy or biochemotherapy) were associated with overall survival (all p<0.001). In multivariate analysis LDH (Hazard ratio [HR] 1.6 [1.3–2.1]; p<0.001), S100B (HR 1.6 [1.2–2.1]; p<0.001) and the presence of brain metastases (HR 1.5 [1.1–1.9]; p = 0.009), but not the type of treatment had significant independent impact. Among those factors normal S100B was the best indicator of long-term survival, which was 12.3% after 5 years for this subgroup. CONCLUSION: Serum S100B is a prognostic marker predicting survival at the time of initiation of first-line treatment in unresectable melanoma patients. Compared to the other independent factors LDH and the presence of brain metastases it is most appropriate to predict long-term survival and requires further prospective investigation in patients treated with new and more potent drugs in metastatic melanoma. Public Library of Science 2013-11-28 /pmc/articles/PMC3842933/ /pubmed/24312329 http://dx.doi.org/10.1371/journal.pone.0081624 Text en © 2013 Weide et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Weide, Benjamin
Richter, Sabina
Büttner, Petra
Leiter, Ulrike
Forschner, Andrea
Bauer, Jürgen
Held, Laura
Eigentler, Thomas Kurt
Meier, Friedegund
Garbe, Claus
Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
title Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
title_full Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
title_fullStr Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
title_full_unstemmed Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
title_short Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy
title_sort serum s100b, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842933/
https://www.ncbi.nlm.nih.gov/pubmed/24312329
http://dx.doi.org/10.1371/journal.pone.0081624
work_keys_str_mv AT weidebenjamin serums100blactatedehydrogenaseandbrainmetastasisareprognosticfactorsinpatientswithdistantmelanomametastasisandsystemictherapy
AT richtersabina serums100blactatedehydrogenaseandbrainmetastasisareprognosticfactorsinpatientswithdistantmelanomametastasisandsystemictherapy
AT buttnerpetra serums100blactatedehydrogenaseandbrainmetastasisareprognosticfactorsinpatientswithdistantmelanomametastasisandsystemictherapy
AT leiterulrike serums100blactatedehydrogenaseandbrainmetastasisareprognosticfactorsinpatientswithdistantmelanomametastasisandsystemictherapy
AT forschnerandrea serums100blactatedehydrogenaseandbrainmetastasisareprognosticfactorsinpatientswithdistantmelanomametastasisandsystemictherapy
AT bauerjurgen serums100blactatedehydrogenaseandbrainmetastasisareprognosticfactorsinpatientswithdistantmelanomametastasisandsystemictherapy
AT heldlaura serums100blactatedehydrogenaseandbrainmetastasisareprognosticfactorsinpatientswithdistantmelanomametastasisandsystemictherapy
AT eigentlerthomaskurt serums100blactatedehydrogenaseandbrainmetastasisareprognosticfactorsinpatientswithdistantmelanomametastasisandsystemictherapy
AT meierfriedegund serums100blactatedehydrogenaseandbrainmetastasisareprognosticfactorsinpatientswithdistantmelanomametastasisandsystemictherapy
AT garbeclaus serums100blactatedehydrogenaseandbrainmetastasisareprognosticfactorsinpatientswithdistantmelanomametastasisandsystemictherapy